News | September 29, 2010

Principal Investigators Announced for St. Jude’s TAVI Trial

September 29, 2010 – Physicians from the Cedars-Sinai Heart Institute will lead a clinical trial evaluating transcatheter aortic valve implantation (TAVI) for patients who experience severe aortic stenosis and who may be at an elevated risk for open-heart surgery. The trial will study St. Jude Medical’s transcatheter aortic valve.

The transcatheter aortic valve is designed to offer increased functionality for transfemoral and transapical implantation.

“St. Jude Medical is pleased to have world-renowned physicians directing the clinical research for our TAVI program,” said Frank J. Callaghan, president of the St. Jude Medical Cardiovascular Division. “Dr. Gregory Fontana and Dr. Raj Makkar have been extensively involved in previous research efforts pertaining to transcatheter aortic valve implantation and are leading authorities for these technologies. We believe this is an important milestone for our program.”

Raj Makkar, M.D., director of interventional cardiology and associate director of the Cedars-Sinai Heart Institute in Los Angeles, has extensive experience in high-risk percutaneous coronary and valvular interventions and the use of advanced percutaneous circulatory support devices. Under Makkar’s direction, Cedars-Sinai physicians completed the most aortic valve replacements in an international clinical trial at more than 20 medical centers. He is a principal investigator for several research protocols involving transcatheter interventions and devices.

Gregory Fontana, M.D., is a cardiac surgeon at the Cedars-Sinai Heart Institute and has been a principal investigator for several research protocols involving transcatheter interventions and minimally invasive surgical devices. As a widely published researcher and author, his writings include more than 80 academic works appearing as articles, book chapters, abstracts and reviews. Published subject matter includes treatments for diseases of the coronary arteries, heart valves, heart transplantation and congenital heart defects.

The St. Jude Medical transcatheter heart valve, made of pericardial tissue, is designed to increase physicians’ control and accuracy during valve deployment. Two delivery methods for the St. Jude Medical transcatheter valve will be evaluated in the trial, the transfemoral and the transapical systems, which are both designed to make transcatheter valve deployment and retrieval easier for clinicians.

The European clinical trial of the St. Jude Medical transcatheter aortic valve is expected to start in 2011.

For more information: sjm.com

Related Content

4C Medical's AltaValve First-in-Human Experience to be Presented at TCT 2018
News | Heart Valve Technology | September 17, 2018
September 17, 2018 — 4C Medical Technologies Inc.
Gore Acquires Pipeline Medical Technologies Inc.
News | Heart Valve Technology | September 06, 2018
W. L. Gore & Associates Inc. (Gore) announced the acquisition of Pipeline Medical Technologies Inc., a privately...
The Edwards Lifesciences Cardioband Tricuspid Valve Reconstruction System received the European CE mark approval in May.

The Edwards Cardioband Tricuspid Valve Reconstruction System received the European CE mark approval in May, becoming the first transcatheter tricuspid repair device to be approved in the world.

Feature | Heart Valve Technology | August 21, 2018 | Jeff Zagoudis
The tricuspid valve has been dubbed “the forgotten valve” by many practitioners in the interventional cardiology spac
Earlier Intervention for Mitral Valve Disease May Lead to Improved Outcomes
News | Heart Valve Technology | July 26, 2018
The number of patients undergoing mitral valve operations are at an all-time high, and new research suggests many...
The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system  is being tested in the SUMMIT Trial.

The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system.

Feature | Heart Valve Technology | July 26, 2018
July 26, 2018 — The pivotal clinical study in the U.S.
A CoreValve TAVR valve seen in a CT scan looking down from the aortic arch into the left ventricle using reconstruction software from TeraRecon.

A CoreValve TAVR valve seen in a CT scan looking down from the aortic arch into the left ventricle using reconstruction software from TeraRecon.

Feature | Heart Valve Technology | July 26, 2018
July 26, 2018 — A new multi-societal expert consensus document has been released that summarizes the position of thes
Abbott Receives FDA Approval for Third-Generation MitraClip Device
Technology | Heart Valve Technology | July 18, 2018
July 18, 2018 — Abbott announced it received approval from the U.S.
Videos | Heart Valve Technology | July 18, 2018
Jonathon Leipsic, M.D., FSCCT, professor of radiology and cardiology at the University of British Columbia, Vancouver
Videos | Heart Valve Technology | July 10, 2018
Ori Ben-Yehuda, M.D., executive director of the Cardiovascular Research Foundation Clinical Trial Center, discusses t
Videos | Heart Valve Technology | July 05, 2018
Rebecca Hahn, M.D., professor of medicine and director of interventional echocardiography, Columbia University Medica
Overlay Init